Evaluation of the validity of chemotherapy-induced XXXX assessment in outpatients using the Japanese version of the MASCC antiemesis tool.

@entity1 @entity390 @entity1209
PURPOSE: The Multinational Association of Supportive Care in Cancer (MASCC) developed the MASCC antiemesis tool (MAT) as a tool for chemotherapy-induced @entity1209 (CINV) assessment and subsequently published its Japanese version in 2010. We evaluated the validity of CINV assessment in outpatients using the Japanese version of MAT. METHODS: @entity1 administered highly or moderately emetogenic chemotherapy in the outpatient chemotherapy unit of our hospital were included in the study. The study was designed as a prospective two-period crossover observational study to evaluate the correlation between the daily @entity1 diary and the Japanese version of MAT in terms of CINV onset. We examined with a focus on reliability of the Japanese version of MAT particularly in the description of the delayed phase of @entity1209 . RESULTS: @entity1 descriptions of CINV onset in a total of 116  cycles in 58 @entity1 (two cycles/ @entity1 ) were analyzed. The CINV incidence indicated by the @entity1 diary was similar to that by the Japanese version of MAT. The concordance rate between the two tools in the same @entity1 was 86.2  % for CINV onset in the delayed phase. The @entity390 score was also similar between the two tools regarding the mean and variance, showing a strong correlation with a correlation coefficient of 0.71. CONCLUSIONS: The results of the study showed that the Japanese version of MAT is a highly reliable tool for CINV assessment, indicating that it is valid for assessing CINV in outpatients.
